Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital downgrades National Grid, sees more limited upside

(Sharecast News) - RBC Capital Markets downgraded National Grid on Wednesday to 'sector perform' from 'outperform' as it said that despite a strong investment proposition, it sees more limited upside at the current share price. RBC said National Grid retains an attractive mix of growth and yield, with a guided circa 10% asset growth compound annual growth rate for FY25-29 well underpinned by strong visibility in the regulated business and a 6-8% EPS CAGR for FY25-29, which may be conservative following the finalisation of RIIO-T3.

"However, we believe that much of this strong performance is acknowledged and incorporated into the current share price," it said, adding that it does not see an imminent catalyst with any revision in the EPS profile unlikely prior to FY26 year-end.

The bank said it was updating for FY25 results with a revised price target of 1,175p, up from 1,150p.

RBC said it continues to see National grid as a strong compounder in the space and believes the business will deliver on its current £60bn capex plan FY25-29.

"However, we struggle for upside at the current share price given an implied circa 35% premium to FY26E RAB in the UK business, whilst our valuation of the US business sits at circa 17x FY26E price-to-earnings."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.